Paul D. Drew

Federal Grant PI High Impact

Professor and Chair

University of Arkansas for Medical Sciences

faculty

Neurobiology & Developmental Science, College of Medicine

drewpauld@uams.edu

39 h-index 85 pubs 4,656 cited

Research Areas

Neuroinflammation and Neurodegeneration Mechanisms Prenatal Substance Exposure Effects Neuroscience and Neuropharmacology Research Immune Response and Inflammation Birth, Development, and Health Substance Abuse Treatment and Outcomes Neurological disorders and treatments Meta-analysis and systematic reviews

Links

ORCID Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Paul D. Drew's research focuses on the neurobiological effects of ethanol exposure, particularly in the context of Fetal Alcohol Spectrum Disorders (FASD) and alcohol use disorder. He investigates how ethanol influences neuroinflammation, myelination, and neurodevelopment in the cerebellum and hippocampus, utilizing mouse models to explore these mechanisms. His work examines the role of innate and adaptive immunity, including signaling pathways such as TLR4 and MyD88, in mediating ethanol-induced neuroinflammation.

In addition to FASD research, Drew also studies Multiple Sclerosis (MS), with a focus on neuroimaging predictors of longitudinal disability and cognition outcomes in patients. His scholarship metrics include an h-index of 39, 85 total publications, and 4,656 total citations, designating him as a highly cited researcher. He has received federal funding from the NIH/National Institute on Alcohol Abuse and Alcoholism for two grants totaling $830,975, both focused on the dynamic neuroimmune interactions in FASD and the role of neuroinflammation in cognitive deficits associated with the disorder. Drew leads an active research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including James C. Douglas, Cynthia J.M. Kane, Tonya Rafferty, and Kalee N. Holloway.

Research Overview

Drew Lab Research: Multiple Sclerosis Fetal Alcohol Spectrum Disorders Neuroimmunology Innate and Adaptive Immunity

Metrics

h-index: 39
Publications: 85
Citations: 4,656

Selected Publications

Targeting the Nlrp3 inflammasome as potential treatment for ethanol-induced non-communicable diseases (2024) DOI
Developmental Ethanol Exposure Impacts Purkinje Cells but Not Microglia in the Young Adult Cerebellum (2024) DOI
Ethanol Induces Neuroinflammation in a Chronic Plus Binge Mouse Model of Alcohol Use Disorder via TLR4 and MyD88-Dependent Signaling (2023) DOI
Developmental ethanol exposure has minimal impact on cerebellar microglial dynamics, morphology, and interactions with Purkinje cells during adolescence (2023) DOI
Ethanol-induced cerebellar transcriptomic changes in a postnatal model of fetal alcohol spectrum disorders: Focus on disease onset (2023) DOI
Cerebellar Transcriptomic Analysis in a Chronic plus Binge Mouse Model of Alcohol Use Disorder Demonstrates Ethanol-Induced Neuroinflammation and Altered Glial Gene Expression (2023) DOI
Effects of chronic and binge ethanol administration on mouse cerebellar and hippocampal neuroinflammation (2022) DOI
Neuroimaging predictors of longitudinal disability and cognition outcomes in multiple sclerosis patients: A systematic review and meta-analysis (2021) DOI
Ethanol effects on cerebellar myelination in a postnatal mouse model of fetal alcohol spectrum disorders (2021) DOI
Ethanol modulation of hippocampal neuroinflammation, myelination, and neurodevelopment in a postnatal mouse model of fetal alcohol spectrum disorders (2021) DOI
Divergent and overlapping hippocampal and cerebellar transcriptome responses following developmental ethanol exposure during the secondary neurogenic period (2021) DOI
Microglia and astrocytes show limited, acute alterations in morphology and protein expression following a single developmental alcohol exposure (2021) DOI
Ethanol modulation of cerebellar neuroinflammation in a postnatal mouse model of fetal alcohol spectrum disorders (2021) DOI

Federal Grants 2 $830,975 total

NIH/National Institute on Alcohol Abuse and Alcoholism Contact PI Sep 2018 - Jun 2024

Dynamic neuroimmune interactions in the onset and progression of FASD

National Institute on Alcohol Abuse and Alcoholism $451,350 R01

NIH/National Institute on Alcohol Abuse and Alcoholism Contact PI Sep 2018 - Aug 2025

Neuroinflammation: Role in FASD Cognitive Deficits

National Institute on Alcohol Abuse and Alcoholism $379,625 R01

Grants & Funding

PPAR-alpha agonists as treatment for autoimmune demyelination National Multiple Sclerosis Society - Pass Through: The Ohio State University Research Foundation Principal Investigator
PPAR-Agonist as Treatment for Autoimmune Demyelination (Subcontract from UT Southwestern Medical Center) National Multiple Sclerosis Society - Pass Through: University of Texas - Southwestern Principal Investigator
LXR agonists as treatment for autoimmune demyelination National Multiple Sclerosis Society Principal Investigator
PPAR-alpha agonists as treatment for autoimmune demyelination National Multiple Sclerosis Society - Pass Through: The Ohio State University Research Foundation Principal Investigator
PPAR-gamma Immune Regulation and Multiple Sclerosis NIH Principal Investigator
Microglia modulate ethanol impact on CNS development. NIH Co-Investigator
Alcohol Pathogenesis in CNS Microglial Cells NIH Co-Investigator
LXR agonists as treatment for autoimmune demyelination National Multiple Sclerosis Society Principal Investigator